Fisetin: The Senolytic Compound Backed by the Mayo Clinic

Fisetin: The Senolytic Compound Backed by the Mayo Clinic

Among the growing list of compounds studied for senolytic activity — the ability to selectively clear senescent ("zombie") cells — fisetin has emerged as one of the most extensively researched, with human clinical trials now being conducted by one of the most respected research institutions in medicine: the Mayo Clinic.

What Are Senescent Cells and Why They Matter

Cellular senescence is a state cells enter when they stop dividing but don't die — instead persisting and secreting a cocktail of inflammatory molecules collectively called the senescence-associated secretory phenotype (SASP). Senescent cells accumulate with age across virtually every tissue and are now understood to be a direct driver of aging and age-related disease, contributing to chronic inflammation, tissue dysfunction, and the progression of conditions ranging from osteoarthritis to atherosclerosis to neurodegeneration.

Senolytics are compounds that selectively induce apoptosis (programmed cell death) in senescent cells while sparing healthy cells — clearing out this dysfunctional cellular debris rather than simply managing its downstream inflammatory effects.

Fisetin's Discovery as a Senolytic

Fisetin is a flavonoid found in modest quantities in strawberries, apples, persimmons, and cucumbers. It was identified as a senolytic candidate through a large screening study conducted by researchers at the Mayo Clinic and Scripps Research Institute, who tested a panel of natural flavonoids for their ability to selectively kill senescent cells in culture.

Among the compounds tested, fisetin showed the most potent senolytic activity — outperforming quercetin, another flavonoid with senolytic properties, in several of the cell culture assays [1]. This finding positioned fisetin as a leading candidate for further development, distinguishing it from broader antioxidant compounds that lack this selective cell-clearing mechanism.

Animal Evidence

The foundational 2018 study that established fisetin's senolytic profile also tested its effects in aged mice. Mice treated with fisetin late in life (beginning at 85 weeks, roughly equivalent to a 75-year-old human) showed reduced senescent cell markers across multiple tissues, reduced age-related pathology, and — most notably — an extension of median lifespan and healthspan compared to untreated aged mice [1].

Subsequent studies have extended these findings to specific disease models. Fisetin treatment reduced senescent cell burden and improved outcomes in mouse models of osteoarthritis, reduced bone loss in models of osteoporosis, and improved markers of kidney function in models of chronic kidney disease — each representing conditions where senescent cell accumulation is understood to play a causal role.

The Mayo Clinic Human Trials

Following the promising preclinical data, the Mayo Clinic has led several early-phase human clinical trials investigating fisetin specifically:

A pilot trial in older adults with frailty (average age 74) tested intermittent high-dose fisetin (20mg/kg/day for two consecutive days) and found it was well-tolerated with no serious adverse events, while showing reductions in circulating markers of senescence and inflammation (including SASP factors) within just a few weeks of the intervention [2].

A separate trial examined fisetin in patients with diabetic kidney disease, again using an intermittent high-dose protocol. The trial found reductions in senescent cell markers in fat tissue biopsies and improvements in certain inflammatory blood markers, providing early proof-of-concept that fisetin's senolytic activity translates from animal models into human tissue [3].

Larger, longer-duration trials are ongoing to determine whether these biomarker improvements translate into meaningful clinical outcomes — slower functional decline, reduced frailty progression, or extended healthy lifespan — which will take considerably more time to establish definitively.

Intermittent Dosing: A Distinguishing Feature

A notable aspect of senolytic research, including fisetin, is the dosing philosophy: unlike most supplements taken continuously every day, senolytics are often studied using "hit-and-run" intermittent dosing — a short burst of high-dose treatment followed by weeks or months without any dosing at all.

This approach reflects the proposed mechanism: senolytics only need to be present long enough to trigger apoptosis in existing senescent cells. Once those cells are cleared, continuous dosing is theoretically unnecessary until senescent cells re-accumulate over time. This is fundamentally different from how NAD+ precursors, omega-3s, or most other longevity supplements are used, and explains why fisetin protocols in the research literature often look different from typical daily-supplementation approaches.

Fisetin vs Quercetin

Quercetin is fisetin's better-known senolytic cousin, and the two are frequently discussed together or combined, particularly alongside dasatinib (a prescription cancer drug) in the "D+Q" senolytic protocol used in some clinical research. In the original Mayo Clinic screening study, fisetin outperformed quercetin's senolytic potency in several cell types, though quercetin has its own separate evidence base (including cardiovascular and antihistamine properties) that fisetin does not share [1].

For someone building a senolytic-focused supplement approach, the two are often viewed as complementary rather than redundant — targeting overlapping but not identical senescent cell populations.

Dosing Considerations

Human trials have generally used substantially higher doses than typical over-the-counter fisetin supplements provide, and on an intermittent rather than daily schedule. The Mayo Clinic trials used approximately 20mg/kg/day (roughly 1,400mg/day for a 70kg adult) for two consecutive days, a dose far higher than the 100-500mg found in most commercial fisetin capsules.

This gap between studied clinical protocols and typical consumer supplementation is worth understanding: daily lower-dose fisetin supplementation, as most people currently take it, has not been directly studied in the same controlled way as the intermittent high-dose protocols used in the Mayo Clinic trials. The optimal consumer approach — dose, frequency, and whether intermittent "hit and run" dosing translates meaningfully at lower doses — remains an open question actively being researched.

Disclaimer: This article is for informational purposes only. Human trial protocols for fisetin have used doses substantially higher than typical commercial supplements, on an intermittent schedule. Consult a physician before beginning any senolytic protocol, particularly if you have any chronic health conditions.

References

[1] Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28.

[2] Hickson LJ et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456.

[3] Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020;288(5):518-536.